JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Open

1.3 -2.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.28

Max

1.33

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.5M 4.9M
Vorige openingsprijs	3.56
Vorige sluitingsprijs	1.3

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: Major Central Bank -2-

24 apr 2026, 19:19 UTC

Acquisities, Fusies, Overnames

Intertek Group Rejects EQT's Revised Offer

26 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 apr 2026, 23:44 UTC

Winsten

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 apr 2026, 23:44 UTC

Winsten

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls Amid Dollar's Strength -- Market Talk

26 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 apr 2026, 05:12 UTC

Winsten

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 apr 2026, 05:12 UTC

Winsten

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 apr 2026, 05:12 UTC

Winsten

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 apr 2026, 05:12 UTC

Winsten

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 apr 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Winsten

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Winsten

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Winsten

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Marktinformatie

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisities, Fusies, Overnames

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisities, Fusies, Overnames

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Marktinformatie

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Marktinformatie

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Winsten

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Winsten

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.